Journal profile · MEDICINE, RESEARCH & EXPERIMENTAL
Life Medicine
ISSN 2755-1733 · Oxford University Press
Life Medicine: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 6.1 (journal website); fully open access; APC about USD 2,750; median 102 days to acceptance (71 articles, last 24 months); 37 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Life Medicine is published by Oxford University Press and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Pluripotent Stem Cells Research, CRISPR and Genetic Engineering and Genetics, Aging, and Longevity in Model Organisms, together about 25.6% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Life Medicine is a basic and translational medical research bimonthly journal published by Higher Education Press and Oxford University Press. Our mission is to accelerate the translation of life science research from bench to bedside by providing a communication platform for the exchange of cutting-edge knowledge and fresh ideas among biomedical researchers and clinicians. Life Medicine publishes Articles, Resources, Reviews, Letters, Previews, Research Highlights, News & Opinions, Forums and other contents commissioned from scientists in the field of biomedical research to promptly disseminate latest significant scientific advances that drive the progress of basic and translational medicine. With the goal to sustainably understand disease mechanisms and improve human health, our current areas of interest include, but are not limited to: Life science Health science Intelligent medicine Reproductive medicine Geriatric medicine Regenerative medicine Pharmacology Genetic disease Infectious disease Cardiovascular disease Respiratory disease Digestive disease Neurological disease Immunological disorder Abstracting and Indexing Information Life Medicine is covered by major indexing/abstracting services, including: CAS DOAJ PMC Scopus Biological Abstracts BIOSIS Previews Emerging Sources Citation Index Journal metrics Citation metrics Clarivate 2025 Impact Factor 7.7 Scopus 2025 CiteScore 6.1 About metrics Disclaimer Statements of fact and opinion in the articles in Life Medicine are those of the respective authors and contributors and not of the Journal, Higher Education Press Limited Company, or Oxford University Press, unless otherwise expressly indicated. Neither Oxford University Press, Higher Education Press Limited Company, nor the Journal make any representation, express or implied, in respect of the accuracy of the material in the Journal and cannot accept any legal responsibility or liability for any errors or omissions that may be made. Readers should make their own evaluation as to the appropriateness or otherwise of the information included.
From the journal's Aims & Scope
Research area (LetPub): MEDICINE, RESEARCH & EXPERIMENTAL
Editor-in-chief Guang-Hui LiuPublisher website
Editorial board by country: 7 in mainland China (about 88%); most named Mainland China 7, United States 1 (8 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Pluripotent Stem Cells ResearchBiochemistry, Genetics and Molecular Biology9%
- CRISPR and Genetic EngineeringBiochemistry, Genetics and Molecular Biology8.5%
- Genetics, Aging, and Longevity in Model OrganismsBiochemistry, Genetics and Molecular Biology8.1%
- Single-cell and spatial transcriptomicsBiochemistry, Genetics and Molecular Biology6.3%
- Mitochondrial Function and PathologyBiochemistry, Genetics and Molecular Biology5.8%
- Adipose Tissue and MetabolismMedicine4.9%
- Telomeres, Telomerase, and SenescenceMedicine4.5%
- Sirtuins and Resveratrol in MedicineMedicine4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PMCCASPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 6.1Publisher website ·
- CiteScore 2026-06
- 6.1LetPub ·
- CiteScore (publisher) 2025
- 6.1Publisher website ·
- SJR 2026-06
- 1.75LetPub ·
- SNIP 2026-06
- 0.44LetPub ·
- h-index
- 22OpenAlex ·
- i10-index
- 60OpenAlex ·
- 2-year mean citedness
- 5.26OpenAlex ·
- Self-citation rate
- 3.9%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 23LetPub ·
Articles by year OpenAlex count · 226 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 35 | 35 | 19 |
| 2025 | 37 | 37 | 194 |
| 2024 | 45 | 45 | 402 |
| 2023 | 50 | 50 | 586 |
| 2022 | 59 | 59 | 706 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
102 daysMedian, submission to acceptance · P25–P75 63 days – 147 days
- Acceptance to online
- median 12 days (71 articles)
- Submission to online
- median 143 days
- Sample
- 71 articles with submission and acceptance dates (77 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to publication (journal-reported)
- about 9 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,750 | Yes | CC BY | |
| OpenAlex | USD 0 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open access
All content published in this journal is open access (OA). Benefits of publishing OA include: Impact and citations Freely available to read and download Comply with funder mandates Learn more about publishing OA
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Oxford University Press
- ISSN
- 2755-1733
- Latest issue on the website
- Volume 5, Issue 4 (August 2026)
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Life Medicine
What CAS zone is Life Medicine in?
In the 2025 upgraded edition of the CAS Journal Ranking, Life Medicine is in Zone 4 of Medicine, and in Zone 4 of the minor category Medicine, Research & Experimental. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Life Medicine?
The journal's website gives an impact factor of 6.1 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 6.1, h-index 22.
How long does peer review take at Life Medicine?
Based on the dates recorded on 71 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 102 days (interquartile range 63–147 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Life Medicine based?
Of the 8 board members whose country the journal's board page names, 7 (about 88%) are in mainland China; the countries named most often are Mainland China (7) and United States (1). Counted from the institutions listed on the board page; for reference only.
Which databases index Life Medicine?
According to LetPub and DOAJ records, Life Medicine is indexed in ESCI, Scopus and DOAJ. The journal's website also lists PMC and CAS; that list has not been checked against each database.
Is Life Medicine open access, and what is the APC?
Life Medicine is a fully open-access journal. APC about USD 2,750.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .